Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, MAD Study to Evaluation of Safety, Tolerability and PK of SHR1314 With Axial Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Vunakizumab (Primary)
- Indications Axial spondyloarthritis
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 11 Jan 2021 Status changed from recruiting to completed.
- 18 Oct 2018 New trial record